Showing results (1-10 of 41) with videos related to
Sort By:
Pageof 5
Cancer Treatment and Research Communications|January 27, 2020
The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testingPanagiotis J Vlachostergios, Bishoy M Faltas, Maria I Carlo, et al.Human Genomics|March 25, 2024
Clinical spectrum of Transthyretin amyloidogenic mutations among diverse population originsAntonella De Lillo, Gita A Pathak, Aislinn Low, et al.Pediatric Blood & Cancer|July 21, 2017
Routine surveillance imaging after end of therapy for pediatric extracranial tumors: A retrospective analysisFarah Lakkis, Sarah Abou Alaiwi, Lena Naffaa, et al.Urologic Oncology|January 13, 2022
Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groupsChethan Ramamurthy, Amin H Nassar, Sarah Abou Alaiwi, et al.Genome Medicine|April 16, 2022
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histologyElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.Clinical Genitourinary Cancer|May 20, 2021
Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial CarcinomaRohit K Jain, William Paul Skelton Iv, Gregory Russell Pond, et al.Journal for Immunotherapy of Cancer|April 3, 2020
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitorsPier Vitale Nuzzo, Gregory R Pond, Sarah Abou Alaiwi, et al.Molecular Cancer Therapeutics|June 10, 2021
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting AgentEddy S Yang, Amin H Nassar, Elio Adib, et al.British Journal of Cancer|December 24, 2021
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancerElio Adib, Talal El Zarif, Amin H Nassar, et al.Clinical Genitourinary Cancer|May 25, 2022
Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitorsPier Vitale Nuzzo, Elio Adib, Nicole Weise, et al.Pageof 5